<p>Canaccord Genuity 分析师 William Plovanic 昨天维持了对 TransMedics Group 的买入评级，并设定了 147.00 美元的目标价。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>William Plovanic 给出买入评级是基于多种因素的组合，这些因素表明 TransMedics Group 的前景乐观。航空数据表明，总航班和飞行小时数可能会增加，反映出与上一季度的季节性下降相比的复苏。这与公司的预估相符，并暗示第四季度的表现将强劲， comparable to earlier quarters in the year。</p>
<p>此外，UNOS 市场数据揭示了器官移植的强劲趋势，特别是在 DCD 肝脏移植方面，超出预期。这些趋势被视为 TransMedics Group 业绩的领先指标。航空和移植数据的结合支持了公司将达到或超过收入预期的预期，从而证明了买入评级的合理性。</p>
<p>在昨天发布的另一份报告中，TR | OpenAI – 4o 也重申了对该股票的买入评级，目标价为 155.00 美元。</p>
<p>TMDX 的价格在过去六个月也略有变化，从 139.400 美元降至 134.800 美元，下降幅度为 -3.30%。</p>

TMDX

<p>Canaccord Genuity 分析师 William Plovanic 维持对 TransMedics Group 的买入评级，理由是航空和移植数据趋势积极。航空数据表明航班恢复，而 UNOS 数据显示器官移植趋势强劲，支持收入预期。另一份报告也重申了买入评级，目标价为 155 美元。TMDX 的股价在六个月内下跌了 3.3%</p>

<p>Canaccord Genuity analyst William Plovanic maintained a Buy rating on TransMedics Group yesterday and set a price target of $147.00.</p>
<div class="lb-trans"><p>Canaccord Genuity 分析师 William Plovanic 昨天维持了对 TransMedics Group 的买入评级，并设定了 147.00 美元的目标价。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>William Plovanic has given his Buy rating due to a combination of factors that suggest a positive outlook for TransMedics Group. The aviation data indicates a potential increase in total flights and flight hours, reflecting a recovery from a seasonal decline in the previous quarter. This aligns with the company’s estimates and suggests a strong performance in the fourth quarter, comparable to earlier quarters in the year.</p>
<div class="lb-trans"><p>William Plovanic 给出买入评级是基于多种因素的组合，这些因素表明 TransMedics Group 的前景乐观。航空数据表明，总航班和飞行小时数可能会增加，反映出与上一季度的季节性下降相比的复苏。这与公司的预估相符，并暗示第四季度的表现将强劲， comparable to earlier quarters in the year。</p>
</div><p>Additionally, the UNOS market data reveals robust trends in organ transplants, particularly in DCD liver transplants, which are ahead of expectations. These trends are considered leading indicators for TransMedics Group’s performance. The combination of aviation and transplant data supports the expectation that the company will meet or exceed revenue estimates, justifying the Buy rating.</p>
<div class="lb-trans"><p>此外，UNOS 市场数据揭示了器官移植的强劲趋势，特别是在 DCD 肝脏移植方面，超出预期。这些趋势被视为 TransMedics Group 业绩的领先指标。航空和移植数据的结合支持了公司将达到或超过收入预期的预期，从而证明了买入评级的合理性。</p>
</div><p>In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $155.00 price target.</p>
<div class="lb-trans"><p>在昨天发布的另一份报告中，TR | OpenAI – 4o 也重申了对该股票的买入评级，目标价为 155.00 美元。</p>
</div><p>TMDX’s price has also changed slightly for the past six months – from $139.400 to $134.800, which is a -3.30% drop .</p>
<div class="lb-trans"><p>TMDX 的价格在过去六个月也略有变化，从 139.400 美元降至 134.800 美元，下降幅度为 -3.30%。</p>
</div>

TransMedics 集团的积极前景：航空和移植数据趋势证明了买入评级的合理性